Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.1M | $20.7M | $48.2M | $53.7M | $24.4M | $20.0M | $16.2M | $16.0M | $15.7M | $13.8M |
| Revenue growth | — | 87.0% | 133.3% | 11.3% | -54.5% | -17.9% | -19.2% | -1.2% | -1.9% | -12.2% |
| Gross profit | $7.00M | $14.5M | $33.9M | $35.1M | $11.0M | $8.62M | $5.55M | $7.08M | $7.17M | $6.75M |
| Gross margin | 63.3% | 70.1% | 70.2% | 65.3% | 45.1% | 43.0% | 34.2% | 44.3% | 45.6% | 49.0% |
| Operating income | -$13.1M | -$4.86M | $10.2M | -$17.2M | -$22.6M | -$18.4M | -$6.85M | $3.36M | -$2.19M | -$470K |
| Operating margin | -118.2% | -23.5% | 21.2% | -32.1% | -92.5% | -92.0% | -42.3% | 21.0% | -13.9% | -3.4% |
| Net income | -$14.1M | -$4.90M | $10.0M | -$16.6M | -$22.3M | -$15.6M | -$8.21M | $3.10M | -$2.39M | -$958K |
| Net margin | -127.9% | -23.7% | 20.7% | -30.9% | -91.2% | -77.6% | -50.7% | 19.4% | -15.2% | -6.9% |
| EPS (diluted) | -$0.27 | -$0.06 | $0.09 | -$0.17 | -$0.22 | -$0.14 | -$0.07 | $0.02 | -$0.01 | -$0.01 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.05M | $3.62M | $12.6M | -$2.23M | -$7.30M | -$7.49M | -$1.89M | $2.25M | -$861K | -$407K |
| Capital expenditures | $17.2K | $454K | $893K | $1.15M | $1.06M | $35.0K | $0.00 | $0.00 | $18.0K | $109K |
| Free cash flow | -$2.07M | $3.16M | $11.7M | -$3.37M | -$8.36M | -$7.52M | -$1.89M | $2.25M | -$879K | -$516K |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | — | $2.79M | $12.9M | $9.61M | $4.53M | $1.38M | $611K | $1.32M | $454K | $278K |
| Total assets | $18.6M | $22.7M | $36.9M | $52.7M | $30.6M | $18.1M | $12.7M | $9.20M | $7.93M | $6.96M |
| Total liabilities | $5.38M | $6.33M | $6.79M | $23.5M | $19.4M | $14.5M | $13.5M | $6.30M | $6.13M | $5.49M |
| Long-term debt | — | — | — | — | $1.45M | $0.00 | — | — | $0.00 | $387K |
| Shareholders' equity | $13.2M | $16.4M | $30.1M | $29.1M | $11.2M | $3.54M | -$777K | $2.90M | $1.79M | $1.47M |
| Retained earnings | -$30.1M | -$35.0M | -$25.0M | -$41.6M | -$63.9M | -$79.5M | -$87.7M | -$84.6M | -$87.0M | -$87.9M |
| Shares (wtd avg diluted) | 57.6M | 80.4M | 114M | 97.9M | 99.9M | 108M | 138M | 154M | 176M | 184M |
Every figure is extracted from CV Sciences, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.